Literature DB >> 7399319

Inflammatory bowel disease associated circulating immune complexes.

B J Kemler, E Alpert.   

Abstract

Circulating immune complexes have been detected in patients with inflammatory bowel disease (IBD). To determine if these complexes are related specificially to IBD or more generally to loss of intestinal mucosal integrity, we compared circulating immune complex levels in the sera of 86 IBD patients, nine pseudomembranous and nine bacterial colitis patients, and 42 healthy controls. Immune complexes were measured by a Raji cell radioimmunoassay. Raji detectable circulating immune complex levels were significantly higher in the IBD group than in the healthy controls (P<0.001). Circulating immune complex levels in the pseudomembranous-bacterial colitis group and the healthy controls were essentially identical. While nearly 20% of the IBD patients (16 of 86) had abnormally high levels, none of the patients with the other forms of intestinal inflammation (0 of 18) had abnormal levels. These data suggest that the circulating immune complexes present in inflammatory bowel disease patients are related to the IBD process rather than to non-specific mucosal cell (barrier) damage. Patients with intestinal inflammation and normal peripheral immune complex levels also had normal mesenteric vein levels. These data suggest that lack of formation, rather than more efficient hepatic reticuloendothelial clearance, was primarily responsible for the absence of detectable complexes in Raji negative individuals. Circulating immune complex levels did not correlate with type, location, severity, or extraintestinal manifestations of inflammatory bowel disease. The absence of Raji detectable circulating immune complexes in the majority of patients, even in those with extraintestinal manifestations, raises serious doubts about the pathogenic significance of such complexes. Nevertheless, as the circulating immune complexes appear to be disease related, they may be used to isolate and identify disease specific antigen(s) of possible aetiological importance.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7399319      PMCID: PMC1420356          DOI: 10.1136/gut.21.3.195

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  21 in total

1.  In vitro studies of inflammatory bowel disease. Surface receptors of the mononuclear cell required to lyse allogeneic colonic epithelial cells.

Authors:  J D Stobo; T B Tomasi; K A Huizenga; R J Spencer; R G Shorter
Journal:  Gastroenterology       Date:  1976-02       Impact factor: 22.682

2.  Soluble immune complexes in sera of patients with nephritis.

Authors:  R D Rossen; M A Reisberg; D B Singer; F X Schloeder; W N Suki; L L Hill; G Eknoyan
Journal:  Kidney Int       Date:  1976-09       Impact factor: 10.612

3.  Immune complexes in ulcerative colitis and Crohn's disease.

Authors:  H J Hodgson; B J Potter; D P Jewell
Journal:  Clin Exp Immunol       Date:  1977-08       Impact factor: 4.330

4.  Evidence for complement-binding immune complexes in adult coeliac disease, Crohn's disease, and ulcerative colitis.

Authors:  W F Doe; C C Booth; D L Brown
Journal:  Lancet       Date:  1973-02-24       Impact factor: 79.321

5.  Circulating immune complexes in inflammatory bowel disease.

Authors:  D P Jewell; I C MacLennan
Journal:  Clin Exp Immunol       Date:  1973-06       Impact factor: 4.330

6.  The Raji cell radioimmune assay for detecting immune complexes in human sera.

Authors:  A N Theofilopoulos; C B Wilson; F J Dixon
Journal:  J Clin Invest       Date:  1976-01       Impact factor: 14.808

7.  The pathogenesis of arthritis associated with acute hepatitis-B surface antigen-positive hepatitis. Complement activation and characterization of circulating immune complexes.

Authors:  J R Wands; E Mann; E Alpert; K J Isselbacher
Journal:  J Clin Invest       Date:  1975-05       Impact factor: 14.808

8.  Circulating immune complexes in the serum in systemic lupus erythematosus and in carriers of hepatitis B antigen. Quantitation by binding to radiolabeled C1q.

Authors:  U E Nydegger; P H Lambert; H Gerber; P A Miescher
Journal:  J Clin Invest       Date:  1974-08       Impact factor: 14.808

9.  Short-term course and prognosis of Crohn's disease.

Authors:  F T De Dombal; I L Burton; S E Clamp; J C Goligher
Journal:  Gut       Date:  1974-06       Impact factor: 23.059

10.  Suggestive evidence that the "blocking antibodies" of tumor-bearing individuals may be antigen--antibody complexes.

Authors:  H O Sjögren; I Hellström; S C Bansal; K E Hellström
Journal:  Proc Natl Acad Sci U S A       Date:  1971-06       Impact factor: 11.205

View more
  12 in total

1.  Sensorineural deafness--a new complication of ulcerative colitis?

Authors:  D Hollanders
Journal:  Postgrad Med J       Date:  1986-08       Impact factor: 2.401

2.  Absence of complement fixing antibodies against lipopolysaccharides from Escherichia coli in a subgroup of patients with Crohn's disease.

Authors:  M Zeitz; U Hope; B Wust; C Galanos; B Möller; T J Lawley; E O Riecken
Journal:  Gut       Date:  1987-11       Impact factor: 23.059

3.  Ulcerative colitis: an overview.

Authors:  A Archambault
Journal:  Can Fam Physician       Date:  1990-02       Impact factor: 3.275

4.  Circulating antibodies to the surface antigens on colon epithelial cells in ulcerative colitis.

Authors:  T Hibi; S Aiso; M Ishikawa; M Watanabe; T Yoshida; K Kobayashi; H Asakura; S Tsuru; M Tsuchiya
Journal:  Clin Exp Immunol       Date:  1983-10       Impact factor: 4.330

5.  Immune complexes in ulcerative colitis.

Authors:  R P Learmonth; E Pihl; W R Johnson
Journal:  Dig Dis Sci       Date:  1984-04       Impact factor: 3.199

6.  Polymorphonuclear leukocyte function in ulcerative colitis and Crohn's disease.

Authors:  A P Kirk; J Cason; J N Fordham; K A Brown; D H Goddard; E J Holborow; J E Lennard-Jones
Journal:  Dig Dis Sci       Date:  1983-03       Impact factor: 3.199

7.  Inflammatory bowel disease and ankylosing spondylitis associated with cutaneous vasculitis, glomerulonephritis, and circulating IgA immune complexes.

Authors:  A J Peeters; A W van den Wall Bake; M R Daha; F C Breeveld
Journal:  Ann Rheum Dis       Date:  1990-08       Impact factor: 19.103

8.  IL-33-dependent induction of allergic lung inflammation by FcγRIII signaling.

Authors:  Melissa Y Tjota; Jesse W Williams; Tiffany Lu; Bryan S Clay; Tiara Byrd; Cara L Hrusch; Donna C Decker; Claudia Alves de Araujo; Paul J Bryce; Anne I Sperling
Journal:  J Clin Invest       Date:  2013-04-15       Impact factor: 14.808

9.  Trauma and the pyoderma gangrenosum of inflammatory bowel disease.

Authors:  S I Finkel; H D Janowitz
Journal:  Gut       Date:  1981-05       Impact factor: 23.059

10.  Ulcerative colitis with arthritis and vasculitis.

Authors:  J C Speiser; T L Moore; J Zuckner
Journal:  Clin Rheumatol       Date:  1985-09       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.